Octreotide and interferon alfa : a new combination for the treatment of malignant carcinoid tumours

• 24 patients with malignant carcinoid tumours received octreotide and interferon alfa (IFN-alpha). All the patients initially received octreotide 50-100 micrograms, twice daily. When progressive symptoms or increasing biochemical markers were observed, the daily dose was raised to a median 300 micrograms. If the initial dose proved ineffective or if no improvement was seen after escalation, IFN-alpha was added (median 9 MU subcutaneously per week). After the addition of IFN-alpha, 17 of the 22 patients (77%) with elevated urinary 5-hydroxyindoleacetic acid showed a significant (> 50%) reduction. Only 1 patient progressed and 4 had continuously stable biochemical disease. No significant reduction in tumour size was noted; in 5 patients, the tumour continued to grow despite decreasing hormone levels. 18 patients had carcinoid syndrome when IFN-alpha was added in 10 (56%) symptoms ameliorated. Thus, the addition of IFN-alpha is beneficial for patients with malignant carcinoid tumours that progress and/or who do not respond to octreotide.

Nyckelord

Adult

Aged

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use

Female

Humans

Hydroxyindoleacetic Acid/urine

Interferon-alpha/therapeutic use

Male

Malignant Carcinoid Syndrome/mortality/*therapy/urine

Middle Aged

Octreotide/therapeutic use

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)